Percent donor EGFP expression in different cells and tissues at 46 weeks after 3 × 500 mg/kg treosulfan and BMT (± 1 SEM)
Group . | Donor PBL granulocytes . | Donor PBL B220 . | Donor PBL CD3 . | Donor BM c-kit . |
|---|---|---|---|---|
| Untreated | ||||
| controls, n = 5 | 0 | 0 | 0 | 0 |
| B6-EGFP.Tg | ||||
| BMT, n = 5 | 8.7 ± 2.0 | 11.0 ± 1.3 | 7.1 ± 0.5 | 8.2 ± 0.9 |
Group . | Donor PBL granulocytes . | Donor PBL B220 . | Donor PBL CD3 . | Donor BM c-kit . |
|---|---|---|---|---|
| Untreated | ||||
| controls, n = 5 | 0 | 0 | 0 | 0 |
| B6-EGFP.Tg | ||||
| BMT, n = 5 | 8.7 ± 2.0 | 11.0 ± 1.3 | 7.1 ± 0.5 | 8.2 ± 0.9 |
Corrected for EGFP expression in B6-EGFP.Tg control mice.